The company, established in late 2019, aims to contribute to the demand in Arab countries for essential, commonly used vaccines, such as those for livestock foot-and mouth disease, bird flu and Newcastle disease, among others.
Free Zone Port of Sohar-Sultanate of Oman
The project will be implemented in two phases:
The Initial capital is OMR 200 thousand, and shareholders are:
Oman Food Investment Holding Company (SAOC)
The company's estimated sales at stability year (the tenth year of production) are estimated at USD 52.7 million
The market share is estimated at 12%.
- Foot Mouth Disease (FMD) vaccine
- Newcastle vaccine, bird flu vaccine, and others
The total investment cost is estimated at USD 55.4 million, representing an investment cost of USD 17.36 million at phase I and USD 38.04 million at phase II in addition to initial working capital estimated at USD 2.55 million.
- Phase I: 50% equity and 50% loans
- Phase II: 32% equity, 64% loans, and 4% internal finance